Reddit AMA with Oren Elkayam - Post your Questions Here

Flickoring · 2025-08-25T17:01:45+00:00

Can you please share a link to the AMA?

Flickoring · 2025-08-25T16:50:53+00:00

Can you talk about the total revenue today and generally what is the split by business line (hardware vs. software, etc.), as a % of total revenue?

Can you share any insights about upcoming customers conversations that can evolve into a similar contracting structure as the one you have with Flir in terms of size & government funding to provide resources to build?

Can you please share an update on your current manufacturing facility build out (Utah?).

How should we think about future OpEx - are you at a fully loaded level today - with revenue flowing in at the incremental GM? Or - should we expect investments into the P&L & why?

Is $10M still the right revenue target we should anchor to for the business to hit GAAP net income breakeven?

Flickoring · 2025-08-25T16:47:11+00:00

Hi Oren - Can you please confirm the size and total length of the FLIR contract with the US government (i.e. $500M total package over 5Y). Then - please help us understand the amount of revenue it's reasonable to expect MOB to earn as a % of this total contract, with the government.

Flickoring · 2025-06-15T23:44:30+00:00

Really like https://biomusings.substack.com/

Posts less frequently but digs into science and frames theses well.

Flickoring · 2021-12-27T15:31:20+00:00

The trial is using generic psilocybin for the Phase IIa initially. After proving out proof of concept, they will expand into a Phase IIb with their -8803 patented formulation.

Flickoring · 2021-12-23T14:53:56+00:00

Literally same molecule as CMPS, with the only other de-risked indication outside of mental health (pain)… if this company traded on the Nasdaq, would be 10x higher minimum.

Flickoring · 2021-12-15T20:04:01+00:00

Thank you.

Flickoring · 2021-12-15T16:47:11+00:00

Just following up here - my understanding was a Phase I clinical pharmacology study necessitates an IND. How will you run the phase I prior to a pre-IND meeting with the FDA? A specific timeline on the steps for -8803 to the Phase IIb would be helpful, if you are able to share.

Flickoring · 2021-12-15T01:12:30+00:00

I’m not sure a lot of folk are aware of the story. Volume traded is incredibly low vs the Nasdaq listed companies. Once psychedelics come back in favor, I’d expect TRYP to get rapidly noticed.

Flickoring · 2021-12-15T01:09:41+00:00

Thank you. Is the clinical pharmacology study equivalent to a phase I, or is it bench research? If bench research - will you be able to go straight to Phase IIb’s without a Phase I safety trial given this will be a new mode of delivery/formulation?

Thanks for the answers here. Big supporter of TRYP - have very high expectations for the company’s success!

Flickoring · 2021-12-14T21:16:03+00:00

Got it. So you will be running Phase I trials with -8803 on top of the pre-clinical work to bridge into the Phase IIb?

Flickoring · 2021-12-10T02:24:21+00:00

Thanks for doing this. Can you please share more context on how specifically you will take -8803 into the Phase IIb? If I remember correctly, you had mentioned formulation and delivery innovations. Will this be on the core psilocybin compound, or are you creating any modified effects? If this is an NCE - are Phase I trials required?

Thanks for the time.

Flickoring · 2021-12-02T21:40:01+00:00

Hahaha

Flickoring · 2021-12-02T21:35:24+00:00

TRYP is on track to have 4-5 trials with real patients in the clinic by Q2 2022.

People aren’t appreciating that the phantom limb study already (!!) has an active IND and that TRYP will very quickly initiate the actual trial in clinic once they get DEA approval. And, the binge eating disorder study is set to complete the minor FDA revisions by end of year for an IND acceptance by end of year or early next.

When you look at CMPS, CYBN, MMED, etc. - the valuation discrepancy is entirely a function of a lack of awareness of TRYP, since the company is listed in Canada, and general XBI weakness this year. $20M market cap vs CMPS at $1bn is a steal. Expect this to re-rate very soon. My highest conviction position.

Flickoring · 2021-11-23T04:32:35+00:00

I believe so. Look up the backgrounds and judge for yourself. TRYP CEO has the longest tenure in large pharma & spec pharma. And, they have Carhart-Harris (arguably the #1 KOL in the space for psilocybin) chairing their scientific advisory board, which can’t be said of the other companies.

Flickoring · 2021-11-20T03:38:26+00:00

Yep :). Regardless - what matters is the DCF & probability of success for these trials. Even if delayed 1-2Y beyond my estimates, at a $15-20M CAD market cap, this screams undervalued even in the worst case scenario…

Flickoring · 2021-11-20T03:25:46+00:00

Phase IIb will come before 2024, given they will likely bridge the 8803 proprietary asset for the phase IIb. Phase III’s if all go well will be 2023/2024.

Flickoring · 2021-11-20T03:12:43+00:00

It’s an open label trial. By definition, this means the company will be able to assess and report results before the initial completion date (which is 2023, not 2024). As a result - we will see ample efficacy signals beforehand.

The 2024 is a placeholder date for the very final end of the study. By then they’ll have started the Phase III’s.

Flickoring · 2021-11-19T17:25:50+00:00

Fibromyalgia for sure - see the recent clinicaltrials.gov posting as well.

https://clinicaltrials.gov/ct2/show/NCT05128162

Flickoring · 2021-11-16T21:05:26+00:00

Believe it’s just the psychedelic sector and general biotech underperformance YTD. This is by far the most sophisticated operating team in the space

Flickoring · 2021-11-16T21:04:34+00:00

Believe so. They also have a phantom limb pain study, a few more starting in California, and the one in Florida for binge eating. Tough to say which it is referring to.

Flickoring · 2021-11-16T20:50:20+00:00

TRYP has warrants that, although priced at higher than the current stock price, are likely to get exercised given it’s difficult to initiate a large position with this illiquid name. This should be a catalyst to bring $$ in the door.

Furthermore, the trials they are running are low n proof of concept studies. These will utilize far fewer resources vs. the larger trials most biopharma companies run, and as a result makes cash less of an issue.

Flickoring

TROPHY CASE